ND-003
/ Shenzhen Xinyue
- LARVOL DELTA
Home
Next
Prev
1 to 4
Of
4
Go to page
1
May 30, 2024
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
(clinicaltrials.gov)
- P1 | N=104 | Enrolling by invitation | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd | Not yet recruiting ➔ Enrolling by invitation
Enrollment open
April 11, 2024
A Study to Evaluate Safety, Tolerability and Pharmacokinetic of ND-003 Tablets in Healthy Adults
(clinicaltrials.gov)
- P1 | N=104 | Not yet recruiting | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd
New P1 trial
March 12, 2024
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
(clinicaltrials.gov)
- P1 | N=96 | Enrolling by invitation | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd | Not yet recruiting ➔ Enrolling by invitation
Enrollment open • Metastases • Oncology • Solid Tumor
December 13, 2023
An Open-label, Phase 1 Study to Determine the Maximum Tolerated Dose of ND-003 in Patients With Advanced Solid Cancers
(clinicaltrials.gov)
- P1 | N=96 | Not yet recruiting | Sponsor: Shenzhen NewDEL Biotech, Co., Ltd
New P1 trial • Oncology • Solid Tumor
1 to 4
Of
4
Go to page
1